Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Webcasts|June 9, 2021
PPD Laboratories’ Suzhou, China Lab Virtual Grand Opening
Author(s)PPD
*Two Live Airings: Wednesday, June 9, 2021 at 9am EDT| 3pm GMT & Wednesday, June 9, 2021 at 12pm EDT| 9am PDT* Join us for a hybrid/virtual event to celebrate the opening of PPD Laboratories’ newest lab in Suzhou, China. Hear from PPD Laboratories leaders, take a virtual tour, and participate in a live Q&A. *On Demand Until June 9, 2022*
Register free:
Event Overview:
Join us for a live virtual grand opening event that will share a first look at PPD Laboratories’ new multi-functional lab in Suzhou, China. This significant expansion will enhance PPD’s bioanalytical, biomarker and vaccine service offerings to support global clinical trials for both China-based and global pharma and biotech customers. The event will include introductory remarks from key laboratory leaders, a virtual tour of the new lab, highlights from the in-person event in China earlier this month, and a live Q&A.
Key Learning Objectives:
- Attendees will learn about the service offerings of PPD Laboratories’ new multi-functional lab in Suzhou, China.
- Attendees will learn about PPD Laboratories’ strategies and goals for growth in China.
- Attendees will learn about PPD’s commitment to global drug and vaccine development and how our lab in Suzhou, China supports these goals.
Time and Date:
Wednesday, June 9, 2021 at 9am EDT| 3pm GMT
Wednesday, June 9, 2021 at 12pm EDT| 9am PDT
Register free:
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5